Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.3552W HIGH $14.00
Volume
888.50 K
Value Traded
6.80 M
Short % Float
20.12%
-5.11%Week
-20.62%1 Month
+1.79%3 Month
+100%6 Month
-0.12%5 Year
-0.12%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
739.17 M
EPS (TTM)
-1.16
P/E Ratio
-
Ent. Value
537.60 M
Total Shares
76.48 M
Float Shares
61.34 M
Insiders
19.83%
Institutions
62.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CADL Catalyst Timeline
Dated clinical, regulatory and corporate events for Candel Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Candel Therapeutics, Inc.
429Total events
16Upcoming
104Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Publicationaglatimagene besadenovecPresentation
Publication of final Phase 2a data of aglatimagene plus valacyclovir in advanced NSCLC
unresectable stage III/IV non-small cell lung cancer (NSCLC) with inadequate response to immune checkpoint inhibitorssource ↗
▲Topline Readoutaglatimagene besadenovecClinical Data
Final Phase 2a results of aglatimagene plus valacyclovir in advanced NSCLC
unresectable stage III/IV NSCLC with inadequate response to ICIsource ↗
●Equity OfferingCorporate
Inducement stock options granted to 4 new employees (85,900 shares at $10.44)
▲Biomarker Dataaglatimagene besadenovecClinical Data
PrTK03 centrally reviewed biopsies showed improved negative biopsy rate and increased lymphocytic infiltration/lymphocyte-tumor mixing after aglatimagene
intermediate-risk localized prostate cancersource ↗
▲Biomarker Dataaglatimagene besadenovecClinical Data
New biomarker data from completed Phase 3 trial of aglatimagene in localized prostate cancer presented at ASTRO 2026
localized intermediate- to high-risk prostate cancersource ↗
▲Poster Presentationaglatimagene besadenovecPresentation
Poster 'Quantitative digital pathology defines immune activation following aglatimagene besadenovec immunotherapy in localized prostate cancer' (Abstract LBA 30) presented at ASTRO 2026
localized intermediate- to high-risk prostate cancersource ↗
●Management ChangeCorporate
Martine Zimmermann, PharmD, appointed to Candel Board of Directors
▲Full Resultsaglatimagene besadenovecClinical Data
Pivotal phase 3 results published in The Lancet Oncology
localized, intermediate- to high-risk prostate cancersource ↗
◆Poster Presentationaglatimagene besadenovecPresentation
Extended biomarker analysis abstract at ASTRO 2026
localized prostate cancersource ↗
▲Trial Initiationaglatimagene besadenovecTrial
Initiation of global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors
advanced non-small cell lung cancersource ↗
▲Partnership / LicenseCorporate
Engagement of Parexel International to support global pivotal trial execution
▲PublicationCAN-2409Presentation
Publication in The Lancet Oncology of pivotal phase 3 data for CAN-2409 in localized prostate cancer
localized prostate cancersource ↗
●Trial Initiationaglatimagene besadenovecTrial
Pivotal phase 3 trial initiation in NSCLC planned for June 2026
progressive, metastatic NSCLC despite ICI treatmentsource ↗
▲Trial Initiationaglatimagene besadenovecTrial
First trial site activated for AURORA phase 3 trial
metastatic non-squamous non-small cell lung cancersource ↗
▲Oral Presentationaglatimagene besadenovecPresentation
Extended follow-up data presented at AUA 2026 Annual Meeting
localized prostate cancersource ↗
◆Quarterly UpdateCorporate
Investor conference call to discuss extended follow-up data from Phase 3 trial
▲Full Resultsaglatimagene besadenovecClinical Data
Extended follow-up data from phase 3 trial with median 58 months follow-up
localized prostate cancersource ↗
▲Full Resultsaglatimagene besadenovecClinical Data
Extended follow-up data from phase 2a NSCLC trial reported (12-month additional follow-up)
advanced NSCLC with inadequate response to ICIsource ↗
▲Oral Presentationaglatimagene besadenovecPresentation
Extended follow-up data presented at AUA 2026
localized, intermediate- to high-risk prostate cancersource ↗
▲Partnership / Licenseaglatimagene besadenovecCorporate
Commercialization agreement with EVERSANA for potential U.S. launch
intermediate- to high-risk, localized prostate cancersource ↗
◆Trial Initiationaglatimagene besadenovecTrial
Phase 3 pivotal trial initiation planned for CAN-2409 in NSCLC non-squamous histology
non-small cell lung cancer, non-squamous histologysource ↗
◆Manufacturing Milestoneaglatimagene besadenovecCMC / Inspection
Process validation by control manufacturer
localized prostate cancersource ↗
▲Partnership / Licenseaglatimagene besadenovecCorporate
Commercialization agreement with EVERSANA for potential U.S. launch
localized prostate cancersource ↗
◆Trial InitiationCAN-2409Trial
Initiation of pivotal phase 3 clinical trial of CAN-2409 in NSCLC expected in Q2 2026
non-small cell lung cancer (NSCLC)source ↗
◆Full Resultsaglatimagene besadenovecClinical Data
Extended follow-up data from phase 3 prostate cancer trial
localized, intermediate- to high-risk prostate cancersource ↗
◆Full ResultsCAN-2409Clinical Data
First results after extended follow-up from phase 3 prostate cancer study
localized prostate cancersource ↗
▲Full Resultsaglatimagene besadenovecClinical Data
Extended follow-up survival data from phase 2a trial of CAN-2409 in advanced NSCLC
advanced non-small cell lung cancersource ↗
▲Topline Readoutaglatimagene besadenovecClinical Data
Extended follow-up data from Phase 3 trial of aglatimagene besadenovec in localized prostate cancer
localized prostate cancersource ↗
▲Topline Readoutaglatimagene besadenovecClinical Data
PrTK03 Phase 3 clinical outcomes in intermediate-risk prostate cancer (41% reduction in recurrence/death risk)
intermediate-risk localized prostate cancersource ↗
▲Additional Dataaglatimagene besadenovecClinical Data
PrTK03 intermediate-risk subgroup showed 41% reduction in recurrence/prostate cancer-specific death risk and improvements in time to biochemical failure, metastasis, and salvage therapy
intermediate-risk localized prostate cancersource ↗
▼Program Discontinuationaglatimagene besadenovecCorporate
Paused PDAC program
borderline resectable pancreatic cancer (PDAC)source ↗
●Abstractaglatimagene besadenovecPresentation
Abstract accepted for oral presentation at AUA 2026
localized prostate cancersource ↗
◆Oral PresentationPresentation
Candel Therapeutics to present at TD Cowen's 46th Annual Health Care Conference
▼Equity OfferingCorporate
Pricing of underwritten public offering of 18,348,624 shares at $5.45 per share for gross proceeds of $100 million
▲Debt Royalty Financingaglatimagene besadenovecCorporate
$100M royalty funding agreement with RTW Investments
localized, intermediate- to high-risk prostate cancersource ↗
◆Oral PresentationCAN-3110Presentation
Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial
recurrent high-grade gliomasource ↗
◆Poster PresentationCAN-3110Presentation
Driving the Use of Biomarker-Based Enrollment in GBM Trials to Accelerate Clinical Success & Improve Patient Outcomes
recurrent high-grade gliomasource ↗
◆Poster PresentationCAN-3110Presentation
Harnessing Omics Data & Molecular Subtyping to Inform Patient Stratification in Clinical & Translational Strategies in Glioblastoma Drug Development
recurrent high-grade gliomasource ↗
●Oral PresentationCAN-3110Presentation
Workshop presentations and panel discussions at Glioblastoma Drug Development Summit
recurrent high-grade glioma (rHGG)source ↗
▲Oral PresentationCAN-2409Presentation
Extended follow-up data presented at AUA 2026 Annual Meeting
localized prostate cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How CADL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | aglatimagene besadenovec | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$702M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
0.9x
rNPV / MCap
Top 10%
Micro Cap(rank 67 of 658)
Percentile Rank
Candel Therapeutics, Inc. carries a moderate pipeline score (56/100), with $1.8B risk-adjusted pipeline value, led by aglatimagene besadenovec in Prostate Cancer (Phase 3), across $112B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| aglatimagene besadenovec Gene therapyNCT02768363 | Prostate Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 898 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CADL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| aglatimagene besadenovec Fast TrackRMATOrphan | unresectable stage III/IV NSCLC | Phase 2a | 2026-10-01 | median overall survival: 24.5 months; m OS progressive disease: 21.5 months; m OS non squamous: 25.4 months; survived beyond 24 months: 37%; non squamous survived beyond 24 months: 14 of 15; non squamous survived beyond 30 months: 9 of 9; exploratory m OS non squamous: 16.7 months; docetaxel benchmark: 9.8 to 11.8 monthsRead More | Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICIRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tak Paul PeterDirector, Officer (Chief Executive Officer) | Sell | -59,379 113,321 held | $10.46 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CADL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.6 % (100 %) | 66.15 M | 6.42 M |
CADL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CADL ranks across every disease it competes in
Competitive Position is a premium feature
See how CADL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCADL News
CADLCandel Therapeutics to Present at the SITC 2026 Annual Meeting
Candel Therapeutics announced its participation in the SITC 2026 Annual Meeting, where it will present findings from its aglatimagene besadenovec program for non-small cell lung cancer and linoserpaturev for recurrent glioblastoma. The presentations will highlight clinical data and mechanistic insights aimed at improving treatment outcomes for cancer patients. The event is scheduled for November 4-8, 2026, in Phoenix, Arizona.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics announced the granting of stock options to four new employees as part of its 2025 Inducement Plan. The options, totaling 85,900 shares at an exercise price of $10.44, will vest over a period contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's ongoing commitment to expanding its workforce as it advances its clinical-stage biopharmaceutical initiatives.
Read more →CADLCandel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Candel Therapeutics announced the publication of Phase 2a trial results for aglatimagene besadenovec combined with valacyclovir, showing a median overall survival of 24.5 months in patients with advanced non-small cell lung cancer (NSCLC) who had inadequate responses to immune checkpoint inhibitors. This result significantly surpasses the historical benchmarks for standard chemotherapy. The treatment was well tolerated, with mild adverse effects reported.
Read more →CADLCandel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
Candel Therapeutics announced promising clinical data from its PrTK05 trial, showing that aglatimagene besadenovec induces significant immune activation and improves disease outcomes in patients with intermediate-risk localized prostate cancer. The findings indicate a 41% reduction in recurrence risk and enhanced immune responses, supporting the upcoming BLA submission to the FDA planned for Q4 2026.
Read more →CADLCandel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Candel Therapeutics presented new data at ASTRO 2026 showing that aglatimagene besadenovec significantly enhances immune engagement in localized prostate cancer. The study revealed that patients treated with aglatimagene exhibited increased lymphocyte infiltration and improved pathologic outcomes compared to those receiving standard care. These findings highlight the potential of aglatimagene to provide durable immune remodeling and better disease-free survival rates.
Read more →CADL▼ -6.9%on this news
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
Candel Therapeutics has appointed Martine Zimmermann, PharmD, to its Board of Directors as the company prepares for a Biologics License Application (BLA) submission for its immunotherapy candidate, aglatimagene besadenovec. Zimmermann brings over 30 years of regulatory and quality experience, which will be crucial as Candel aims for commercial readiness. The company has seen encouraging results in clinical trials for aglatimagene, which targets various solid tumors.
Read more →CADLCandel Therapeutics to Present at September Investor Conferences
Candel Therapeutics will participate in several investor conferences in September 2026, where CEO Paul Peter Tak will engage in discussions and meetings. The company is focused on developing multimodal immunotherapies for cancer treatment, with notable advancements in their clinical trials. Candel's lead product candidate, aglatimagene, has shown positive outcomes in phase 2a trials and has received multiple FDA designations.
Read more →CADL▲ +10.5%on this news
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported its Q2 2026 financial results, highlighting plans to submit a Biologics License Application for aglatimagene in prostate cancer by Q4 2026. The company published pivotal phase 3 data showing improved disease-free survival for aglatimagene in prostate cancer patients. Additionally, they activated the first trial site for a phase 3 trial in NSCLC and appointed a new Chief Commercial Officer to aid in commercialization efforts.
Read more →CADLCandel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Candel Therapeutics announced that an abstract detailing the Phase 3 results of Aglatimagene besadenovec will be presented at the ASTRO Annual Meeting in September 2026. The study focuses on immune activation in localized prostate cancer. The company has received various FDA designations for this treatment, highlighting its potential in oncology.
Read more →CADLCandel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
Candel Therapeutics, a clinical-stage biopharmaceutical company, will present at Canaccord Genuity's 46th Annual Growth Conference in Boston from August 11-13, 2026. The presentation is scheduled for August 12 at 12 PM EDT. Candel focuses on developing multimodal immunotherapies for cancer, with successful clinical trials for its lead product candidates.
Read more →CADLCandel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics announced the granting of stock options to Mark Sims, the new Chief Commercial Officer, as part of an inducement plan under Nasdaq Listing Rule 5635(c)(4). The options, totaling 285,000 shares at an exercise price of $10.03, will vest over four years. Candel focuses on developing innovative immunotherapies for cancer treatment, with promising clinical trial results for its lead product candidates.
Read more →CADLCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics has launched the global pivotal Phase 3 AURORA trial to evaluate aglatimagene besadenovec in combination with valacyclovir and pembrolizumab for patients with advanced non-small cell lung cancer (NSCLC). The trial aims to enroll patients across over 150 sites, focusing on overall survival as the primary endpoint. The initiative builds on promising Phase 2 trial results, addressing a critical need for effective treatments in this patient population.
Read more →CADLCandel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer to lead the commercial strategy for aglatimagene besadenovec, aimed at treating localized prostate cancer. The company plans to submit a Biologics License Application in Q4 2026, with a potential launch in 2027. This appointment is part of Candel's strategy to transition into a commercial-stage oncology company.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Candel Therapeutics announced the grant of stock options to three new employees, totaling 63,000 shares at an exercise price of $8.30. This grant is part of the company's 2025 Inducement Plan and aligns with Nasdaq Listing Rule 5635(c)(4). Candel continues to advance its clinical-stage immunotherapies, including successful trials for its lead product candidate, aglatimagene.
Read more →CADLCandel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics has published pivotal Phase 3 data in The Lancet Oncology, demonstrating a 30% improvement in disease-free survival for localized prostate cancer patients treated with aglatimagene besadenovec combined with radiotherapy. The study showed no significant increase in toxicity and supports a planned Biologics License Application for aglatimagene in late 2026. The findings highlight the potential of aglatimagene to improve outcomes for patients with high-risk localized prostate cancer.
Read more →CADLCandel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics has reported positive extended follow-up results from its Phase 3 trial of aglatimagene besadenovec in localized prostate cancer. The data showed a 39% improvement in disease-free survival compared to placebo, with significant benefits observed in secondary endpoints. The findings were presented at the AUA 2026 Annual Meeting, reinforcing the potential of aglatimagene to enhance treatment outcomes.
Read more →CADLForward-looking statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contai
Candel Therapeutics presented forward-looking statements regarding their clinical trials and product candidates, specifically focusing on the Phase 3 trial of aglatimagene besadenovec in localized prostate cancer. The data suggest that the combination of aglatimagene besadenovec and prodrug with external beam radiation therapy shows accumulating benefits for patients. However, the projections are subject to various risks and uncertainties, including reliance on third parties and potential discrepancies between forecasts and actual outcomes. The company emphasizes caution in relying on these forward-looking statements, as they carry inherent risks and assumptions.
Read more →About Candel Therapeutics, Inc.
Headquarters117 KENDRICK STREET, NEEDHAM, MA, 02494
BIOPHARMAWATCH ELITE PLUS
Trade the next CADL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime